Research programme: skin atrophy therapeutics - TopimedAlternative Names: DIK 61
Latest Information Update: 02 Oct 2015
At a glance
- Originator Topimed
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Skin disorders
Most Recent Events
- 06 Jun 2005 Preclinical trials in Skin disorders in Israel (Topical)